C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients.

Area of Science:

• Immunology
• Nephrology
• Hematology

Background:

• Atypical hemolytic uremic syndrome (aHUS) is a severe thrombotic microangiopathy driven by complement alternative pathway activation.
• Current anti-C5 antibody treatments improve prognosis but cause systemic complement inhibition, increasing infection risk.
• Targeted complement inhibitors offer a potential strategy to localize drug activity and preserve systemic complement function.

Purpose of the Study:

• To evaluate the local complement inhibitory activity of novel anti-C3d antibody conjugates.
• To assess the efficacy of these targeted inhibitors in preventing complement-mediated endothelial dysfunction and pro-thrombotic effects in aHUS.

Main Methods:

• Tested anti-C3d monoclonal antibody 3d8b conjugated with CR1 (CR1_1-10, CR1_1-17) or Factor H (FH_1-5).
• Assessed inhibition of C3 deposition and C5b-9 formation on human microvascular endothelial cells (HMEC-1) exposed to aHUS patient serum.
• Evaluated prevention of loss of anti-thrombogenic properties in HMEC-1 cells.

Main Results:

• Targeted anti-C3d conjugates effectively prevented complement activation on HMEC-1 cells, outperforming non-targeted inhibitors.
• Inhibitor efficacy varied (CR1_1-17 > CR1_1-10 > FH_1-5) for C3 convertase inhibition but all blocked C5 convertase activity.
• All tested conjugates eliminated the pro-thrombotic effects induced by aHUS patient serum.

Conclusions:

• Tissue-targeted complement inhibition using anti-C3d antibody conjugates is a viable therapeutic strategy for aHUS.
• This approach offers localized complement control, potentially avoiding systemic immunosuppression and infection risks.
• These findings support further development of non-systemic complement inhibitors for localized complement dysregulation diseases.